Low back pain affected 619 million people in 2020 and is the single leading cause of disability worldwide. Cases are projected to rise 36% to 843 million by 2050, driven by population growth and ageing, with the sharpest increases in Asia and Africa.
118 of these 221 molecules are fixed-dose combinations, among them 15 thiocolchicoside presentations and 13 with proteolytic enzymes.
Range depth
9 etoricoxib and 29 aceclofenac presentations.
15 thiocolchicoside presentations, 12 paired with an analgesic.
13 trypsin presentations.
Controlled-substance lines are supplied subject to narcotics licensing in both jurisdictions.
Tell us the market and what you already stock.
Start the conversation